Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12386255 | 0.87 | GRM4 (0.60) | GRM4ALDH1A1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL5952099 | 0.86 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2MAPK1LMNAALOX15 | |
| SCHEMBL1851780 | 0.85 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2MAPK1LMNAALOX15 | |
| SCHEMBL30492996 | 0.85 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2MAPK1LMNAALOX15 | |
| SCHEMBL31184650 | 0.84 | GRM4 (0.61) | GRM4ALDH1A1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL258201 | 0.82 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2MAPK1LMNAALOX15 | |
| SCHEMBL30675560 | 0.82 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2MAPK1LMNAALOX15 | |
| SCHEMBL5755555 | 0.81 | GRM4 (0.55) | GRM4ALDH1A1SMN1; SMN2MAPK1LMNA | |
| SCHEMBL9447193 | 0.81 | CYP1A2 (0.56) | GRM4ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL11487853 | 0.81 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPK1HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022087475-A1 | REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES COMPRISING UNNATURAL NUCLEOTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2020252262-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2019014262-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS OF USE IN VIVO THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| EP-2189449-A1 | AMINOPYRAZOLE AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-4981856-A | QUINAZOLINE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | AAK1, ADCK1, ANKK1 | GRM4 4172/4885ALDH1A1 2563/4885SMN1; SMN2 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.